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Abstract
Caprylic acid purification of IgG, currently used in the manufacture of horse-derived antivenoms, was successfully adapted
for the preparation of sheep and camel IgG. Sheep IgG had a molecular mass of w150 kDa, whereas camel IgG presented two
bands of molecular masses of w160 and 100 kDa, the latter corresponding to heavy-chain IgG, which is devoid of light chains.
Horse, sheep and camel IgGs were compared by several parameters aiming at predicting their potential for induction of early
and late adverse reactions. Horse and sheep IgGs showed a higher anticomplementary activity than camel IgG, and also elicited
a higher anti-IgG response than camel IgG, when injected in mice. Horse IgG agglutinated human type OC erythrocytes,
whereas no such reactivity was observed in sheep and camel IgG preparations. A novel procedure was used for the detection of
antibodies in human serum against animal IgGs. It was found that a pool of human sera collected in Costa Rica had a higher titer
of antibodies directed against horse and sheep IgGs than against camel IgG. Overall, camel IgG showed the lowest potential for
the induction of adverse reactions among the three IgGs tested.
q 2005 Elsevier Ltd. All rights reserved.
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Parenteral administration of heterologous antivenom
preparations constitutes the mainstay in the therapy of
envenomations by animal bites and stings (Theakston et al.,
2003). A great variety of antivenoms are currently produced
in many laboratories from the serum of animals, mostly
horses and sheep, that are immunized with single or multiple
venoms. There are three main types of antivenom0041-0101/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
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E-mail address: jgutierr@icp.ucr.ac.cr (J.M. Gutie´rrez).preparations, depending on the nature of the neutralizing
molecules: (a) whole IgG preparations, (b) F(ab 0)2 prep-
arations, and (c) Fab preparations (Theakston et al., 2003).
F(ab 0)2 and Fab antivenoms are obtained by pepsin or
papain digestion of IgGs, respectively, with the resultant
elimination of Fc fragment. These three types of antivenoms
differ in their pharmacokinetic characteristics, an issue that
has evident implications in their pharmacodynamic per-
formance (Gutie´rrez et al., 2003; Theakston et al., 2003).
Caprylic acid fractionation of animal sera or plasma
constitutes a highly convenient methodology for immuno-
globulin purification (Steinbuch and Audran, 1969). This
method is currently being used in antivenom production,
and can be applied not only in the manufacture of wholeToxicon 46 (2005) 775–781www.elsevier.com/locate/toxicon
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but also in the production of F(ab 0)2 and Fab antivenoms
(Dos Santos et al., 1989; Leo´n et al., 2000). Whole IgG
antivenoms prepared by caprylic acid fractionation of horse
plasma have been shown to be highly safe and effective in
the treatment of snakebites in Central and South America
(Arroyo et al., 1999; Otero et al., 1999). Owing to the
simplicity and low cost of this procedure, it may become a
highly useful fractionation methodology for the manufac-
ture of antivenoms in regions of the world where a serious
crisis in antivenom accessibility currently exists, such as
in sub-Saharan Africa (Theakston and Warrell, 2000;
Gutie´rrez et al., 2005).
Parenteral antivenom administration is often associated
with early and delayed adverse reactions (Warrell, 1995),
with a high variation in their incidence depending upon the
product being administered (Cardoso et al., 1993; Otero
et al., 1999; Lalloo and Theakston, 2003). Several
mechanisms have been proposed to cause adverse reactions
to antivenoms: (a) complement activation due to the
presence of Fc in whole IgG preparations, or to the presence
of protein aggregates in antivenoms made of whole IgG or
its fragments (Sutherland, 1977; Otero et al., 1999); (b)
immunogenicity of antivenom proteins which would elicit
an anti-IgG antibody response associated with delayed
reactions, i.e. serum sickness (Leo´n et al., 2001; Lalloo and
Theakston, 2003); (c) the presence of preservatives in
antivenom preparations, which may elicit various adverse
effects (Garcı´a et al., 2002). However, the actual mechan-
isms responsible for such adverse reactions are difficult to
demonstrate in patients, and thus remain largely unknown.
Despite the fact that caprylic acid-fractionated horse-
derived whole IgG antivenoms have shown a good safety
profile in clinical trials, mild early adverse reactions have
been reported in 10–25% of patients receiving these
products (Arroyo et al., 1999; Otero et al., 1999). Therefore,
it is of relevance to further investigate the mechanisms
behind these adverse reactions, in order to minimize them
and to make these antivenoms even safer.
There has been little effort to compare horse and sheep
IgGs regarding their propensity to induce early and delayed
adverse reactions. In addition, other animals may be
considered as potential sources of plasma or serum for
antivenom production. In Africa, for instance, camelids
may become a valuable new source of hyperimmune
plasma for antivenom production, as recently shown for
an antivenom to treat scorpion stings in Tunisia
(Meddeb-Mouelhi et al., 2003). The aim of this work was
two fold: (a) to adapt the methodology used for caprylic
acid purification of equine IgG to camel plasma, in order to
determine if it could be of use in the event of utilizing
camels in antivenom production, and (b) to compare IgGs
purified by this procedure from the plasma of horses, sheep
and camels regarding several characteristics that might be
associated with the development of adverse reactions to the
administration of antivenoms.2. Materials and methods2.1. Plasma fractionation and IgG purification
The procedure described by Rojas et al. (1994) was
followed, with several modifications. In the cases of horse
and sheep IgG, citrated plasma was the starting material,
obtained after sedimentation at 4 8C of blood collected from
five adult sheep and ten adult horses, respectively, kept at
Instituto Clodomiro Picado. In the case of camel,
fractionation was performed on serum, obtained by
centrifugation after clotting of blood collected from one
healthy adult dromedary (Camelus dromedarius) kept in
Senegal. For the purification of IgGs, caprylic acid was
added to plasma or serum, at a ratio of 5 mL acid added to
100 mL plasma or serum. The mixture was stirred for 2 h at
20–22 8C, filtered through 8 mm filter paper and diafiltered.
Then, the preparations were formulated in order to have
0.15 M NaCl, 2.5 g/L phenol and 0.05 g/L thimerosal, at a
final pH of 7.0. The three IgG preparations were
standardized as to have a final protein concentration of
6 g/L. Finally, the preparations were sterilized by filtration
through 0.22 mm membrane and bottled in 10 mL glass
vials.2.2. Electrophoretic analysis
The same amount of IgG protein for each preparation
was loaded in SDS-polyacrylamide gels, at an acrylamide
concentration of 7.5 g/dL, and electrophoretic separations
were performed under non-reducing conditions (Laemmli,
1970). Proteins were stained with Coomassie Brilliant Blue
R-250. Molecular mass standards were run in parallel.2.3. In vitro anticomplementary activity
Dilutions of each IgG preparation, using barbital buffer,
pH 7.6 as diluent, were prepared in triplicate. Then, 0.5 mL
of fresh human plasma, diluted 1:5 in barbital buffer, were
added to 2.0 mL of each IgG dilution. After an incubation of
1 h at 37 8C, 100 mL of a suspension of sheep erythrocytes
previously sensitized with rabbit anti-sheep erythrocyte
antibodies were added, and the mixture was incubated for
1 h at 37 8C (Leo´n et al., 2005). Then, 2 mL of cold barbital
buffer were added, the tubes were immediately centrifuged
and the absorbance of supernatants at 540 nm was recorded.
Human plasma samples were run in parallel by incubating
them with barbital buffer, in the absence of heterologous
IgG. The rest of the procedure was performed as described,
and complement activity in these conditions was considered
100%. Anticomplementary activity of IgG preparations was
expressed as percentage, relative to the activity of these
controls.
Fig. 1. SDS-PAGE of IgGs isolated from horse and sheep plasma,
and from camel serum. Aliquots of each IgG preparation, previously
diluted 1:2 in buffer and containing 15 mg protein, were separated
by electrophoresis in 7.5% acrylamide gels under non-reducing
conditions. Proteins were stained with Coomassie Brilliant Blue R-
250. Lanes 1, 3 and 5 correspond to crude horse plasma, camel
serum and sheep plasma, respectively. Lanes 2, 4 and 6 correspond
to purified horse, camel and sheep IgGs. Estimated molecular
masses are depicted to the left.
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Groups of ten CD-1 mice of both sexes (16–18 g) were
bled and serum was separated, to obtain a pre-immune
serum sample. Then, mice were injected by the intra-
peritoneal route with 500 mL of either horse, sheep or camel
IgG preparation. After 15 days, mice were bled under CO2
anesthesia into heparinized microcapillary tubes. Then,
plasma was separated by centrifugation and the anti-IgG
antibody titer was assessed by ELISA. Plates were coated
with 100 mL of a 1:1000 dilution of either horse, sheep or
camel IgG preparation. After an incubation of 24 h at room
temperature, plates were washed five times with 0.12 M
NaCl, 0.04 M sodium phosphate, pH 7.2 buffer (PBS), and
then 100 mL of mouse plasma, diluted 1:2000 in 2% bovine
serum albumin (BSA)-PBS, were added to each well. After
1 h of incubation at room temperature, plates were washed
five times with PBS, and 100 mL of peroxidase-conjugated
anti-mouse IgG, diluted 1:1000 with 2% BSA-PBS were
added, followed by an incubation of 1 h at room
temperature. Finally, o-phenylendiamine (OPD) and H2O2
was added for color development, and absorbances recorded
at 492 nm.
2.5. Antibodies against animal IgG in human serum
In order to detect if normal human serum contains
antibodies against animal IgGs, microplates were coated
with 100 mL of 1:1000 dilutions of either human, horse,
sheep or camel IgGs, purified by caprylic acid fractionation.
After washing the plate five times with PBS, 50 mL of
biotinylated human IgG (obtained by caprylic acid
fractionation from a pool of 10 adult healthy Costa Rican
volunteers), diluted 1:500 in 2% BSA-PBS, were added and
the plates incubated for 1 h at 20–22 8C. Then, plates were
washed five times with PBS, and 100 mL of avidin
conjugated with peroxidase, diluted 1:2000 with PBS/2%
BSA, were added to each well, followed by an incubation of
1 h at 37 8C. Color was developed by the addition of H2O2
and OPD, and the absorbances at 492 nm were recorded.
This test avoids the use of an anti-human secondary
antibody, in order to rule out the possible interactions of
this secondary antibody with animal IgG due to heterophile
antibodies known to be present in animal serum (Willman
et al., 1999).
2.6. Agglutination of human erythrocytes
The presence of antibodies in IgG preparations able to
agglutinate human erythrocytes was tested by adding
100 mL of various dilutions of the three IgG preparations
to 50 mL of a 5% suspension of human OC erythrocytes in
PBS. Controls included erythrocytes incubated with PBS
alone. After incubation for 1 min at 20–22 8C, tubes were
centrifuged at 500g for 30 s and macroscopic agglutination
observed.2.7. Statistical analysis
The significance of the differences between the mean
values of two experimental groups was determined by the
Student’s t-test. When more than two groups were
compared, analysis of variance was performed, followed
by a Tukey-Kramer test. A p value%0.05 was considered
significant.3. Results3.1. Caprylic acid purification of IgG
The procedure previously used for the purification of
horse IgG, based on caprylic acid precipitation of non-IgG
plasma proteins (Rojas et al., 1994; Gutie´rrez et al., 2005),
was successfully applied to sheep plasma and to camel
serum. Electrophoretic analysis of the three preparations
showed a broad predominant band of 120–150 kDa in horse
IgG preparation, a band of w150 kDa in sheep IgG
preparation, and two bands of w160 and 100 kDa in
camel IgG preparation (Fig. 1). These findings agree with
previous observations indicating that horse and sheep IgGs
have molecular masses of approximately 150 kDa, whereas
camel serum contains IgGs of two different molecular
masses due to the presence in camelid serum of both
1.2
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Fig. 2. Anticomplementary activity of IgG preparations. Human
plasma was incubated with various dilutions of the three IgG
preparations. Then, the mixtures were added to a suspension of
sheep erythrocytes previously sensitized with anti-sheep erythro-
cyte rabbit antibodies. After incubation, tubes were centrifuged and
the absorbance of the supernatants was recorded at 540 nm. As
control, human plasma was incubated with barbital buffer instead of
IgG, and the rest of the procedure performed as described.
Anticomplementary activity was evidenced by a reduction in the
complement activity of human plasma after incubation with IgGs.
Results are presented as meanGSD. Horse antibodies: empty bars;
sheep antibodies, diagonal ascending bars; camel antibodies,
diagonal descending bars. Horse and sheep IgGs exerted a
significantly higher anticomplementary activity than camel IgG
when tested undiluted (p!0.05), whereas no anticomplementary
activity was detected at higher dilutions in any of the IgG
preparations.
Fig. 3. Antibody response in groups of ten CD-1 mice against IgGs.
Mice were bled to obtain a sample of preimmune serum. Then, they
received an intraperitoneal injection of 500 mL of either horse,
sheep or camel IgG. After two weeks, mice were bled again and
serum separated. Anti-IgG response was assessed by ELISA in
plates coated with the corresponding IgG used in the immunization.
After addition of anti-mouse IgG conjugated with peroxidase
followed by the substrate, absorbances were recorded at 492 nm.
For each animal, the absorbance of preimmune serum samples was
subtracted from the absorbance of samples collected after
immunization. Results are presented as meanGSD. Camel IgG
induced a significantly lower antibody response than horse and
sheep IgGs (*p!0.05), whereas no significant differences occur in
the response to horse and sheep IgGs.with camel IgG developed a significantly lower antibody
response (Fig. 3).3.4. Antibodies against animal IgGs in human serum
The enzyme immunoassay developed in this work
allowed us to compare the titer of anti-IgGs from different
species in a pool of human sera, thus allowing the detection
of antibodies in human serum against animal IgGs. As
shown in Fig. 4, highest absorbances were recorded in plates
coated with sheep IgG, followed by horse IgG. In contrast,
no significant differences were found when plates were
coated with either human or camel IgGs (Fig. 4), evidencing
the lack of antibodies against camel IgG in the pool of
human sera used.3.5. Agglutination of human erythrocytes
As shown in Table 1, horse IgGs induced a strong
agglutination of human erythrocytes, whereas no macro-
scopic agglutination was observed when using sheep or
camel IgG preparations.
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Fig. 4. Detection of antibodies against horse, sheep or camel IgG in
a pool of human sera from ten individuals. Plates were coated with
100 mL of a 1:1000 dilution of either human (empty bars), horse
(diagonal ascending bars), sheep (diagonal descending bars) or
camel (crossed bars) IgGs. Then, various dilutions of biotinylated
human IgG were added, followed by an avidin-peroxidase
conjugate and peroxidase substrate. Absorbances were recorded at
492 nm. Results are presented as meanGSD. A significantly higher
absorbance (p!0.05) was recorded in wells coated with horse or
sheep IgGs than in those coated with human or camel IgGs.
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A very simple and convenient methodology, based on
caprylic acid precipitation of non-IgG proteins in plasma or
serum, has been adapted in various laboratories for the
production of equine-derived antivenoms (Dos Santos et al.,
1989; Rojas et al., 1994; Gutie´rrez et al., 2005). In this work
it has been demonstrated that this procedure can be also
applied in the purification of IgGs from sheep and camel
sera. In the case of camel serum, this adaptation opens the
possibility for the production of this type of antivenom inTable 1
Agglutination of human group OC erythrocytes by horse, sheep
and camel IgG preparations purified by caprylic acid precipitation
of non-IgG plasma proteins
Dilution of IgG Agglutination
Horse IgG Sheep IgG Camel IgG
1 4C – –
3 3C – –
9 – – –
27 – – –
Dilutions of IgG in PBS were incubated with a 5% suspension of
human OC erythrocytes in PBS. After centrifugation, agglutination
was observed macroscopically and graded from –(no agglutination)
to 4C(strong agglutination).African countries, where a particularly serious crisis
currently exists in the provision of antivenoms (Theakston
and Warrell, 2000). Camelids like the dromedary are
abundant in sahelian and savanna areas of Africa, where
they are highly adapted; this species can yield a large
volume of blood. A previous study showed the effectiveness
of immunizing dromedaries with scorpion venoms in
northern Africa for the production of neutralizing IgGs
(Meddeb-Mouelhi et al., 2003). Furthermore, it has been
suggested that, owing to the low structural complexity of the
antigen-binding sites of heavy-chain camelid antibodies,
they may become useful inhibitory molecules (Lauweyers
et al., 1998) that may be of value for a variety of purposes,
including neutralization of toxins. In our study, two bands of
mol. mass of 160 and 100 kDa were observed; they are
likely to correspond to classical IgGs having two light and
two heavy chains, and IgGs constituted only by two heavy
chains, i.e. IgGs devoid of light chains (Hamers-Casterman
et al., 1993; Meddeb-Mouelhi et al., 2003). Thus, caprylic
acid precipitation allows the purification of both types of
IgGs from camelid serum.
Early and late adverse reactions occur in a number of
patients receiving antivenoms of different sources and made
of different neutralizing molecules (Cardoso et al., 1993;
Otero-Patin˜o et al., 1998). Despite the widely held
assumption that the presence of Fc in whole IgG antivenom
preparations is the main cause of these adverse reactions
(see for example Chippaux, 1998), clinical observations
indicate that the mechanisms behind such reactions go
beyond the presence of Fc fragments. There are caprylic
acid-fractionated whole IgG antivenoms that induce a low
incidence of adverse reactions (Otero-Patin˜o et al., 1998;
Otero et al., 1999). Therefore, there is not a clear correlation
between the presence of Fc fragment and the incidence of
early adverse reactions.
Anticomplementary activity has been proposed as a key
mechanism in the induction of early adverse reactions after
administration of human and heterologous IgG preparations
(Barandun et al., 1962; Sutherland, 1977). Previous studies
have demonstrated anticomplementary activity in both
whole IgG and F(ab 0)2 equine-derived antivenoms (Montero
et al., 1989; Otero et al., 1999; Leo´n et al., 2001). Our
observations indicate that horse and sheep IgGs exert this
activity on human serum, whereas camel IgGs did not
activate complement in these experimental conditions. The
reason behind this interesting observation is not known, but
may have to do with the peculiar biochemical features of
camel IgGs (Hamers-Casterman et al., 1993), a hypothesis
that remains open for future studies.
The development of serum sickness is the most common
manifestation of late adverse reaction after administration of
heterologous antivenoms (Warrell, 1995), although its
actual incidence has not been properly investigated. Serum
sickness, which is a typical type III hypersensivity reaction,
is directly proportional to the immunogenicity of heter-
ologous antivenoms. In order to predict the propensity of
M. Herrera et al. / Toxicon 46 (2005) 775–781780development of this type of late adverse reaction in the
three types of IgGs analyzed in this study, we immunized
groups of mice with the same amount of protein from each
IgG preparation. Observations indicate that horse and sheep
IgG induce a similar antibody response in mice, thus
raising doubts on the concept that horse IgG is more
immunogenic than sheep IgG (Landon and Smith, 1996), at
least in this experimental model. In contrast, a significantly
lower anti-IgG antibody response developed in mice
injected with camel IgG, suggesting that it is less
immunogenic than horse and sheep IgGs. Furthermore,
single-domain antibody fragments of camelid IgG, com-
prising only the variable domain of heavy chain antibodies,
are effective antigen-binding fragments devoid of immu-
nogenicity (Cortez-Retamozo et al., 2002).
When incubated with human erythrocytes, horse IgG
induced agglutination, thus evidencing the presence of
antibodies against erythrocyte membrane components.
These antibodies might be specific for such antigens or
may correspond to ‘heterophile’ antibodies, which are poly-
specific and agglutinate erythrocytes of various species
(Levinson and Miller, 2002). In contrast, no such
agglutination was observed when sheep or camel IgGs
were incubated with human erythrocytes. The clinical
significance of antibodies agglutinating erythrocytes in
equine-derived antivenoms has not been established,
although our observations indicate that no deleterious
effects on erythrocytes occur after intravenous injection of
horse IgG antivenom in rabbits (Leo´n et al., 2005).
Nevertheless, the role played by these antibodies in the
early adverse reactions to antivenoms requires further
investigation.
A number of workers have shown that human serum
contains antibodies against IgGs from various animals,
even when they have not been previously injected with
these IgGs. It has been speculated that this antibody
response may be secondary to sensitization to animal IgG
either by ingestion through the food or by exposure to
animal hair and dander (Hunter and Budd, 1980;
Bernhisel-Broadbent et al., 1991; Ayuso et al., 2000).
Since there is a conspicuous cross-reactivity between IgGs
of different animal sources (Esteves and Binaghi, 1972),
exposure or ingestion of IgG from an animal species may
sensitize people to IgG of a different animal source.
Regardless of the mechanism of sensitization, the exposure
of humans, particularly in rural areas, to horses, sheep or
camel may induce a sensitization to animal IgG. Thus,
when an intravenous infusion of relatively large amounts of
these heterologous proteins is performed during antivenom
therapy, such antibodies may react with animal IgGs in the
circulation, forming immune complexes and activating the
complement system, with the consequent release of
anaphylatoxins and the onset of early adverse effects.
Such mechanism would be involved only in early adverse
reactions and not in late adverse effects associated with
serum sickness.The immunoassay developed in this study evidenced the
presence of anti-sheep and anti-horse IgGs in the pool of
human sera used, whereas the absorbances of wells coated
with camel IgGs were similar to those of wells coated with
human IgG. The fact that the pool of sera tested corresponds
to blood samples collected in Costa Rica agrees with this
result, as sheep and especially horses are abundant in this
country, whereas there has been no previous exposure to
camel serum proteins in these people. Hence, it is proposed
that a potential mechanism for the induction of early adverse
reactions to heterologous antivenom administration might
be the existence of anti-animal IgG antibodies in the serum
of patients receiving antivenom, as a consequence of
previous sensitization to these proteins. To the best of our
knowledge, this represents a novel mechanism to explain the
early adverse reactions in heterologous antivenom
administration.
In conclusion, the methodology for IgG purification
based on the precipitation of non-IgG proteins by caprylic
acid was successfully adapted for the purification of sheep
and camel IgGs. When the different IgG preparations were
compared for their potential for induction of adverse
reactions, camel IgG showed the lowest propensity to
induce adverse reactions. This supports the use of camelid
antibodies in the preparation of antivenoms.Acknowledgements
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